Cure My Disease

Don't miss your cure!

 Log in / Sign up

Glowing dye could reveal hidden cancer spread in testicular tumors

NCT ID NCT07699640

Disease control Sponsor: Heinrich-Heine University, Duesseldorf Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This trial investigates whether a minimally invasive procedure using a special dye can better detect cancer spread in men with early-stage testicular cancer. About 20-30% of these patients have cancer cells in lymph nodes that standard scans miss. Participants are randomly assigned to receive either standard surgery plus a dye-guided lymph node biopsy or standard surgery alone. The goal is to see if the dye-guided approach improves relapse-free survival and reduces unnecessary treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Indocyanine green (ICG) dye
What this could lead to
If successful, this approach could provide more accurate staging for early testicular cancer, helping to avoid unnecessary treatments while catching hidden spread earlier.
What could go wrong
This is a relatively early-stage trial with 171 participants, so results may not apply broadly. The procedure carries surgical risks, and the dye may not identify all affected lymph nodes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 171 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Jan 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male participants aged 18 years or older. * Clinically suspected testicular germ cell tumor based on physical examination and scrotal ultrasonography, with or without elevated serum tumor markers (AFP and/or β-hCG). * No radiological evidence of metastatic disease on preoperative contrast-enhanced computed tomography (CT) of the chest and abdomen (clinical stage I). * Eligible for radical inguinal orchiectomy. * Able to understand the study procedures and provide written informed consent. * Willing and able to comply with the study protocol and follow-up schedule. Exclusion Criteria: * Previous scrotal or retroperitoneal surgery unrelated to germ cell tumor treatment, except surgery for cryptorchidism during childhood. * Previous malignancy requiring abdominal surgery, chemotherapy, or radiotherapy that could interfere with study participation. Previous radiotherapy involving the retroperitoneum. * Known hypersensitivity to indocyanine green (ICG), iodine, or sodium iodide. * Severe medical condition that precludes surgery or study participation. * Psychiatric disorder or other condition preventing compliance with study procedures. * Inability to understand the German language sufficiently to provide informed consent and complete study assessments. * Individuals under legal guardianship or otherwise unable to provide legally valid informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Testicular cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

testicular cancer testicular germ cell tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Testicular cancer Testicular germ cell tumor

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Asklepios Klinik Altona

    Hamburg, Free and Hanseatic City of Hamburg, 22763, Germany

  • Helios University Hospital Wuppertal

    Wuppertal, North Rhine-Westphalia, 42283, Germany

  • Helsinki University Hospital

    Helsinki, 00014, Finland

  • University Hospital Cologne

    Cologne, North Rhine-Westphalia, 50937, Germany

  • University Hospital Dresden

    Dresden, Saxony, 01307, Germany

  • University Hospital Düsseldorf

    Düsseldorf, North Rhine-Westphalia, 40225, Germany

  • University Hospital Marbug

    Marburg, Hesse, 35043, Germany

  • University Hospital Ulm

    Ulm, Baden-Wurttemberg, 89081, Germany

  • University Hospital Würzburg

    Würzburg, Bavaria, 97080, Germany

  • University of Turku

    Turku, 20520, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.